Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
Rattachement africain : be, us, th, ua, es, ru, tr, de, kr, fr, ca, pl, jp, se. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. Perioperative therapy may improve outcomes in this population. METHODS: In this phase 3, open-label trial, participants with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy were randomly assigned to perioperative (neoadjuvant and adjuvant) enfortumab vedotin, an antibody-drug conjugate directed at nectin-4, plus pembrolizumab and surgery (9 total cycles of enfortumab vedotin [1.25 mg per kilogram of body weight on days 1 and 8] plus 17 total cycles of pembrolizumab [200 mg on day 1 every 3 weeks], with surgery after 3 cycles) or surgery alone (control). The primary end point was event-free survival. Key secondary end points were overall survival and pathological complete response (absence of viable tumor after surgical resection). Other secondary end points included safety. RESULTS: A total of 344 participants underwent randomization (170 in the enfortumab vedotin-pembrolizumab group and 174 in the control group). At data cutoff, median follow-up was 25.6 months (range, 11.8 to 53.7). Surgery was performed in 87.6% of participants in the enfortumab vedotin-pembrolizumab group and in 89.7% in the control group. At 2 years, estimated event-free survival was 74.7% in the enfortumab vedotin-pembrolizumab group and 39.4% in the control group (hazard ratio for an event or death, 0.40; 95% confidence interval [CI], 0.28 to 0.57; two-sided P<0.001); estimated overall survival was 79.7% and 63.1% (hazard ratio for death, 0.50; 95% CI, 0.33 to 0.74; two-sided P<0.001). A pathological complete response had occurred in 57.1% and 8.6% of the participants (estimated difference, 48.3 percentage points; 95% CI, 39.5 to 56.5; two-sided P<0.001). Adverse events occurred in all participants in the enfortumab vedotin-pembrolizumab group (grade ≥3, 71.3%; grade ≥3 drug-related, 45.5%) and in 64.8% in the control group (grade ≥3, 45.9%). CONCLUSIONS: Perioperative enfortumab vedotin plus pembrolizumab and surgery led to significantly better event-free and overall survival outcomes and a greater percentage of participants with pathological complete response than surgery alone in a predominantly cisplatin-ineligible population with muscle-invasive bladder cancer. Safety was also assessed. (Funded by Merck Sharp and Dohme, a subsidiary of Merck [Rahway, NJ]; KEYNOTE-905 ClinicalTrials.gov number, NCT03924895.).
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
- Date Crossref
- 02/04/2026
- Éditeur
- Massachusetts Medical Society
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Antwerp pays non établi dans la noticeUniversité ou école supérieure
-
Antwerp Management School pays non établi dans la noticeUniversité ou école supérieure
-
AZ Maria Middelares pays non établi dans la noticeÉtablissement de santé
-
Indiana University Health pays non établi dans la noticeÉtablissement de santé
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Indiana University – Purdue University Indianapolis pays non établi dans la noticeUniversité ou école supérieure
-
Siriraj Hospital pays non établi dans la noticeÉtablissement de santé
-
Mahidol University pays non établi dans la noticeUniversité ou école supérieure
-
Lviv State University of Internal Affairs pays non établi dans la noticeUniversité ou école supérieure
-
Hospital Del Mar pays non établi dans la noticeÉtablissement de santé
-
Parkview Health pays non établi dans la noticeÉtablissement de santé
-
Federal Medical-Biological Agency pays non établi dans la noticeOrganisme public
University of Antwerp, Antwerp Management School et AZ Maria Middelares, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.